Skip to content
    Reviews

    ICIs Combined With TACE Improve Progression-Free Survival in Unresectable HCC

    Cioni et alNature reviews. Clinical oncology

    The systemic treatment landscape for unresectable hepatocellular carcinoma has been transformed by immune-checkpoint inhibitor (ICI)-based regimens, prompting efforts to combine ICIs with locoregional therapies (LRTs) to improve tumour control and extend clinical benefits to patients with intermediate-stage disease. The underlying rationale for this strategy centers on the capacity of LRTs—specifically transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and external beam radiotherapy (EBRT)—to induce immunogenic cell death, promote tumour antigen release, and reprogramme the immunosuppressive tumour microenvironment.
    Clinical evidence includes five phase III trials that have shown improvements in progression-free survival and objective response rates with regimens combining ICIs with TACE. Furthermore, early-phase and real-world evidence supports combining ICIs with TARE or EBRT, specifically in selected patients with portal vein tumour thrombosis or focal lesions unsuitable for standard embolization.
    Despite these developments, clinical integration faces persistent challenges, including optimal patient selection, therapy sequencing, and response assessment. In addition, demonstrating survival advantages in trials has become increasingly difficult due to widespread post-progression treatment crossover and the availability of effective subsequent therapies. Future progress depends on refining trial design, imaging modalities, and biomarker-driven patient selection.

    Key Takeaways

    • Across five phase III clinical trials, regimens combining immune-checkpoint inhibitors with transarterial chemoembolization have shown improvements in progression-free survival and objective response rates.
    • Early-phase and real-world data support combining immune-checkpoint inhibitors with transarterial radioembolization or external beam radiotherapy in selected patients with portal vein tumour thrombosis or focal disease unsuitable for embolization.
    Read the original sourceNature reviews. Clinical oncology